Johnson & Johnson (NYSE: JNJ) Stock Soars on Strong Q2 Earnings and Raised Outlook

Font: Financial Modeling Prep  • Jul 15, 2026

• Johnson & Johnson (NYSE: JNJ) received a raised price target from Stifel Nicolaus, indicating a potential upside of 5.25%.
• The healthcare giant reported strong Q2 2026 financial results, beating market estimates with $25.30 billion in sales and $2.90 adjusted EPS.
• Driven by its Innovative Medicine division, Johnson & Johnson raised its full-year revenue guidance to between $100.30 billion and $101.30 billion and adjusted EPS guidance to $11.45 to $11.65.

Johnson & Johnson (NYSE: JNJ) is a major global healthcare company. It operates through two main segments. The Innovative Medicine division focuses on developing treatments for serious diseases, particularly in oncology. Its MedTech division provides a wide range of medical devices used in surgery, orthopedics, and other healthcare fields.

On July 15, 2026, analyst Rick Wise of Stifel Nicolaus raises the price target for Johnson & Johnson to $260.00. At the time of the update, the stock's price is $247.02. This new target represents a potential upside of approximately 5.25% for the company's shares, signaling a positive market outlook.

This positive investment outlook is supported by the company's strong financial results. As highlighted by Zacks, Johnson & Johnson's second-quarter 2026 earnings and sales beat market estimates. The company reports quarterly sales of $25.30 billion, a 6.60% increase from the year before, and adjusted earnings of $2.90 per share.

The revenue growth is largely driven by the Innovative Medicine division, with key pharmaceuticals Darzalex and Tremfya showing significant sales increases. This strong performance helps offset challenges from the drug Stelara, which is facing a loss of market exclusivity. The MedTech division also contributes with year-over-year growth.

Following these results, management raises its full-year financial forecast. The company now projects revenue between $100.30 billion and $101.30 billion. It also increases its guidance for adjusted earnings per share (EPS), a measure of profitability, to a range of $11.45 to $11.65 for the year.